Everything below concerns Forced degradation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-09. Numbers and descriptions here follow the published literature rather than marketing material.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
{\displaystyle {\begin{aligned}{\frac {D\omega _{i}}{Dt}}&={\frac {\partial \omega _{i}}{\partial t}}+v_{j}{\frac {\partial \omega _{i}}{\partial x_{j}}}\\&=\omega _{j}{\frac {\partial v_{i}}{\partial x_{j}}}-\omega _{i}{\frac {\partial v_{j}}{\partial x_{j}}}+e_{ijk}{\frac {1}{\rho ^{2}}}{\frac {\partial \rho }{\partial x_{j}}}{\frac {\partial p}{\partial x_{k}}}+e_{ijk}{\frac {\partial }{\partial x_{j}}}\left({\frac {1}{\rho }}{\frac {\partial \tau _{km}}{\partial x_{m}}}\right)+e_{ijk}{\frac {\partial B_{k}}{\partial x_{j}}}\end{aligned}}}
== Fourth round proper == The draw for the fourth round was made on 8 January 2023, consisting of the 32 winners from the previous round. The round included one team from the fifth tier, the lowest-ranked team remaining in the competition: Wrexham.
Dihydrowogonin is a natural product, which as a flavonoid belongs to the flavanone subclass. It has a flavan backbone with a hydroxyl and methoxy functional groups. It possesses some antioxidant, anti-inflammatory, and neuroprotective properties. Dihydrowogonin has been identified as a major constituent in the methanol extract of the species, Prunus avium (wild cherry), mostly in the bark. Dihydrowogonin appears to exhibit antimicrobial and antibiofilm behaviour, particularly against the Gram-positive bacteria like Staphylococcus aureus. In addition, it can interact with glutathione transferases in white-rot fungi; thus, this suggests a role in the detoxification processes during wood degradation. It has been studied for potential applications in pharmacology, particularly as an antimicrobial and antioxidant agent, and in neuroprotective therapies.
=== Prize money === In April 2026, FIFA confirmed the prizes for all participating nations. The total distribution of prize money for the expanded tournament was $871 million, nearly double the amount from the 2022 World Cup. Of this total, $671 million was allocated for performance-based prizes, with the remaining $200 million paid out among teams regardless of performance. Each qualified team received preparation money in the amount of $2.5 million; a team that was eliminated in the group stage would receive a minimum total amount $12.5 million at the tournament, with the winner receiving a total of $52.5 million.
=== History === Hammond, George S. (1997). "Physical organic chemistry after 50 years: It has changed, but is it still there?" (PDF). Pure Appl. Chem. 69 (9): 1919–22. doi:10.1351/pac199769091919. S2CID 53723796. Retrieved 20 June 2015. [An outstanding starting point on the history of the field, from a critically important contributor, referencing and discussing the early Hammett text, etc.]
Sources: en.wikipedia.org
Dry ice can be used for loosening asphalt floor tiles or car sound deadening material, making them easy to prise off, as well as freezing water in valveless pipes to enable repair. One of the largest mechanical uses of dry ice is blast cleaning. Dry ice pellets are shot from a nozzle with compressed air, combining the power of the speed of the pellets with the action of the sublimation. This can remove residues from industrial equipment. Examples of materials removed include ink, glue, oil, paint, mold and rubber. Dry ice blasting can replace sandblasting, steam blasting, water blasting or solvent blasting. The primary environmental residue of dry ice blasting is the sublimed CO2, thus making it a useful technique where residues from other blasting techniques are undesirable. Recently, blast cleaning has been introduced as a method of removing smoke damage from structures after fires. Dry ice is also useful for the de-gassing of flammable vapours from storage tanks –the sublimation of dry ice pellets inside an emptied and vented tank causes an outrush of CO2 that carries with it the flammable vapours. The removal and fitting of cylinder liners in large engines requires the use of dry ice to chill and thus shrink the liner so that it freely slides into the engine block. When the liner then warms up, it expands, and the resulting interference fit holds it tightly in place. Similar procedures may be used in fabricating mechanical assemblies with a high resultant strength, replacing the need for pins, keys or welds.
In June 1945, the squadron initially flew missions with the 310th Fighter Squadron, often twice a day, using borrowed U.S. aircraft. It received 25 new P-47D-30-RA aircraft in July, marked with the insignia of both the USAAF and Mexican Air Force. The squadron flew more than 90 combat missions, totaling more than 1,900 hours of flight time. It participated in the Allied effort to bomb Luzon and Formosa to push the Japanese out of those islands. It relentlessly attacked the Japanese forces concentrated mainly in Luzon and flew 53 combat missions as part of the U.S. Air Force warfare organization, was specified in the support of the 25th Infantry Division, the Philippine Army, as well as numerous Filipino guerrillas, to open up into the Cagayan valley where the squadron devastated the Japanese defenses on the ground with its bombs. Close support missions consisted mainly of attacking resistance points, apart from these they launched attacks on bases, fortifications, supply routes and machine gun pits. During its fighting in the Philippines, five squadron pilots died (one was shot down, one crashed, and three ran out of fuel and died at sea); and three others died in accidents during training. The pilot Héctor Espinoza Galván was flying together with an American pilot but he ran out of fuel and fell into the ocean; His body was never found. Captain Pablo Ribaz Martínez and Second Lieutenant Guillermo García Ramos were surrounded by a storm, Ribaz Martínez dying while García Ramos survived after being rescued.
== Family == The Hoffmann-La Roche family is Switzerland's richest and one of the most secretive families. Many members of the family don't carry the last name Hoffmann anymore. Some are known as Oeri, Michalski, Faber-Castell, Fabre, Schmid or Duschmalé.
== Genetics == Contrary to bacteria and fungi, most plant metabolic pathways are not grouped into biosynthetic gene clusters, but instead are scattered as individual genes. Some exceptions have been discovered: steroidal glycoalkaloids in Solanum, polyketides in Pooideae, benzoxazinoids in Zea mays, triterpenes in Avena sativa, Cucurbitaceae, Arabidopsis, and momilactone diterpenes in Oryza sativa.
Sources: en.wikipedia.org
=== Clinical trials === In a 2010, clinical trial, 34% of patients with refractory Hodgkin lymphoma achieved complete remission and another 40% had partial remission. Tumor reductions were achieved in 94% of patients. In ALCL, 87% of patients had tumors shrink at least 50% and 97% of patients had some tumor shrinkage. Reports in 2013, showed interim results from a Phase II, open-label, single-arm study designed to evaluate the antitumor activity of brentuximab vedotin in relapsed or refractory CD30-positive NHL, including B-cell neoplasms. These results demonstrated that single-agent brentuximab vedotin induced a 42% objective response rate and manageable safety profile among advanced diffuse large B-cell lymphoma patients. A phase III trial funded by Millennium Pharmaceuticals compared ABVD (a combination of the chemotherapy drugs doxorubicin, bleomycin, vinblastine, and dacarbazine) versus A+AVD (a combination of brentuximab vedotin plus AVD, or doxorubicin, vinblastine, and dacarbazine) for treatment of classical Hodgkin lymphoma and found substituting brentuximab vedotin for bleomycin has both improved efficacy and lowered toxicity. A previously completed phase I study demonstrated that a greater number of patients experienced pulmonary toxicity with brentuximab vedotin-ABVD than with ABVD alone. Pulmonary fibrosis is a classical adverse effect of bleomycin; however, the incidence of pulmonary fibrosis in the brentuximab vedotin-ABVD arm was higher than the expected historical rate with ABVD alone.
Over time, most of the strains of bacteria and infections present will be the type resistant to the antimicrobial agent being used to treat them, making this agent now ineffective to defeat most microbes. With the increased use of antimicrobial agents, there is a speeding up of this natural process.
Photodynamic therapy (PDT) is a form of phototherapy using nontoxic light-sensitive compounds (photosensitizers) that are exposed selectively to light at a controlled wavelength, laser intensity, and irradiation time, whereupon they generate toxic reactive oxygen species (ROS) that target malignant and other diseased cells. Oxygen is thus required for activity, lowering efficacy in highly developed tumors and other hypoxic environments. Selective apoptosis of diseased cells is difficult due to the radical nature of ROS, but may be controlled for through membrane potential and other cell-type specific properties' effects on permeability or through photoimmunotherapy. In developing any phototherapeutic agent, the phototoxicity of the treatment wavelength should be considered.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
Liquid chromatography combined with mass spectrometry is the most common approach. Digestion followed by peptide mapping verifies the sequence and modification sites. Results are judged against a reference standard or a theoretically calculated mass.